DAPA

SPECIFICATION

5mg & 10mg

Generics

Dapagliflozin 

About

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Dosage

According to HBA 1c level

Side Effects

 Vomiting • Stomach ache (abdominal pain) • Muscle cramps • A general feeling of not being well with severe tiredness • Difficulty in breathing • Reduced body temperature and heartbeat .

Drug Interactions

ACE inhibitors , Flouroquinolones , SGLT2 inhibitors

When not to Use

History of a serious hypersensitivity reaction to dapagliflozin.Severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis.

Precaution

It causes intravascular volume contraction. Symptomatic hypotension can occur after initiating dapagliflozin particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before initiating dapagliflozin in patients, volume status should be assessed and corrected. Monitor for signs and symptoms of hypotension after initiating therapy.